Bictegravir/emtricitabine/tenofovir alafenamide in a virologically suppressed adult with HIV and end-stage renal disease on chronic peritoneal dialysis: A case report

Abstract

Despite increasing rates of renal replacement therapy, data supporting the safe and effective use of HIV treatment guidelines preferred regimens in people on hemodialysis or peritoneal dialysis is limited. Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a guideline recommended initial regimen for most people with HIV with FDA-approval for use in virologically suppressed people receiving chronic hemodialysis; however, the safety and efficacy of BIC/FTC/TAF remains unknown when used in patients on chronic ambulatory peritoneal dialysis (CAPD). We report the first case of BIC/FTC/TAF use in CAPD.

Keywords

Human immunodeficiency virus viral disease antiviral antiretroviral therapy treatment AIDS viral disease

Get full access to this article

View all access options for this article.

References

Abraham

Althoff

Jing

, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis 2015; 60: 941–949.

Lucas

Ross

Stock

, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis 2014; 59: e96–e138. DOI: 10.1093/cid/ciu617

Ekrikpo

Kengne

Bello

, et al. Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. PLoS One 2018; 13: e0195443. DOI: 10.1371/journal.pone.0195443

Naicker

Rahmanian

Kopp

. HIV and chronic kidney disease. Clin Nephrol 2015; 83: 32–38.

Heron

Bagnis

Gracey

. Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV. AIDS Res Ther 2020; 17: 11. DOI: 10.1186/s12981-020-00266-3

Dandachi

Fabricius

Saad

, et al. Antiretrovirals for people with HIV on dialysis. AIDS Patient Care and STDs 2022; 36: 86–96.

Gilead Sciences . Biktarvy (Package Insert). Foster City, CA, USA: Gilead Sciences, 2021.

Eron

Wilkin

Ramgopal

, et al. A daily single tablet regimen (STR) of bictegravir/emtricitabine/tenofovir alafenamide (b/F/TAF) in virologically-suppressed adults living with HIV and end stage renal disease on chronic hemodialysis. Open Forum Infect Dis 2020; 7: S529–S530. DOI: 10.1093/ofid/ofaa439.1188

Collins

. Introduction. Home Dial Jpn 2012; 177: 1–2.

10.

Murphy

. Clinical pharmacokinetics. 6th ed. Bethesda, MA, USA: American Society of Health-System Pharmacists, Inc., 2021, pp. 31–37.

11.

Steubl

Roos

Hettwer

, et al. Comparison of peritoneal low-molecular-weight-protein-removal in CCPD and CAPD patients based on C-terminal agrin fragment clearance. Kidney Blood Press Res 2016; 41: 175–185.

12.

Janknegt

Koelman

. Drug therapy in continuous ambulatory peritoneal dialysis patients. Pharmaceutisch Weekblad Scientific Edition 1987; 9: 104–109.

13.

National Center for Biotechnology Information . PubChem compound database-bictegravir, 2022, https://pubchem.ncbi.nlm.nih.gov/compound/Bictegravir (Accessed 15 June 2022).

14.

National Center for Biotechnology Information . PubChem compound database-emtricitabine, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/Emtricitabine (Accessed June 15, 2022).

15.

National Center for Biotechnology Information . PubChem compound database-tenofovir alafenamide, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/gs-7340 (Accessed June 15, 2022).

16.

National Center for Biotechnology Information . PubChem compound database-tenofovir, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/464205 (Accessed 15 June 2022).

17.

National Center for Biotechnology Information . PubChem compound database-cobicistat, 2022, https://pubchem.ncbi.nlm.nih.gov/compound/25151504 (Accessed 15 June 2022).

18.

National Center for Biotechnology Information . PubChem compound database-lamivudine, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/60825 (Accessed June 15, 2022).

19.

National Center for Biotechnology Information . PubChem compound database-abacavir, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/441300 (Accessed 15 June 2022).

20.

National Center for Biotechnology Information . PubChem compound database-darunavir, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/213039 (Accessed 15 June 2022).

21.

National Center for Biotechnology Information . PubChem compound database-dolutegravir, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/54726191 (Accessed June 15, 2022).

22.

National Center for Biotechnology Information . PubChem compound database-rilpivirine, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/6451164 (Accessed June 15, 2022).

23.

Custodio

Fordyce

Garner

, et al. Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment. Antimicrob Agents Chemother 2016; 60: 5135–5140.

24.

D:A:D Study Group, Sabin

Signe

, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417–1426.

25.

Ryom

Lundgren

El-Sadr

, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. The Lancet HIV 2018; 5: e291–e300. DOI: 10.1016/s2352-3018(18)30043-2

26.

Maggiolo

Rizzardini

Molina

, et al. Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with hiv: results of a 96 week, phase 3B, open‐label, switch trial in virologically suppressed people ≥65 years of age. HIV Med 2022. Epub ahead of print 2022. DOI: 10.1111/hiv.13319

27.

Nachega

Parienti

J-J

Uthman

, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 2014; 58: 1297–1307.

28.

Ramjan

Calmy

Vitoria

, et al. Systematic review and meta-analysis: patient and programme impact of fixed-dose combination antiretroviral therapy. Trop Med Int Health 2014; 19: 501–513.